Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:04 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26,614 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: CTRL Clear all
Completed Phase 2 Interventional

Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia

NCT00116129
View directory record Official record
Conditions
Fibromyalgia
Interventions
Ibutamoren Mesylate (MK-0677)
Drug
Lead sponsor
Bennett, Robert, M.D.
Individual
Eligibility
30 Years to 65 Years · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Nov 3, 2026, 5:04 AM EST
Completed Phase 3 Interventional Results available

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

NCT02997202
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
gilteritinib, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
46
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Nov 3, 2026, 5:04 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers

Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss

NCT00163137
View directory record Official record
Conditions
Osteoporosis
Interventions
lasofoxifene, raloxifene, Placebo
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
48 Years to 75 Years · Female only
Enrollment
540 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
72
States / cities
Albany, California • Berkeley, California • La Jolla, California + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2011 · Synced Nov 3, 2026, 5:04 AM EST
Completed Phase 4 Interventional Results available

Study on the Effects of Intravenous Dexmedetomidine on Pain in Patients Undergoing Elective Spinal Surgery

NCT03325972
View directory record Official record
Conditions
Chronic Pain
Interventions
Dexmedetomidine, Placebo Saline
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Nov 3, 2026, 5:04 AM EST
Terminated Phase 1 Interventional

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

NCT04807972
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
ABBV-927, Budiglimab, modified FOLFIRINOX
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Aurora, Colorado • Baltimore, Maryland • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Nov 3, 2026, 5:04 AM EST
Completed Not applicable Interventional

Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors

NCT03953157
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Arthralgia, Postmenopausal, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
Interventions
Dietary Intervention, Exercise Intervention, Questionnaire Administration
Dietary Supplement · Behavioral · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Nov 3, 2026, 5:04 AM EST
Completed Phase 3 Interventional Results available

A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers

NCT01087801
View directory record Official record
Conditions
Pancreatic Disease
Interventions
ChiRhoStim, Placebo
Drug
Lead sponsor
ChiRhoClin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Nov 3, 2026, 5:04 AM EST
Completed Phase 3 Interventional Results available

Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne

NCT00776919
View directory record Official record
Conditions
Acne Vulgaris
Interventions
clindamycin / benzoyl peroxide gel, clindamycin gel, BPO gel, vehicle gel
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years to 45 Years
Enrollment
1,315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
16
States / cities
San Diego, California • Santa Monica, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Nov 3, 2026, 5:04 AM EST
Completed Phase 2 Interventional

Efficacy and Safety Study of JNJ-32729463 for Treating Complicated Skin and Skin Structure Infections Compared to Linezolid (Zyvox)

NCT01128530
View directory record Official record
Conditions
Complicated Skin and Skin Structure Infections
Interventions
JNJ-32729463, linezolid, JNJ-32729463 placebo, linezolid placebo
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
27
States / cities
Anaheim, California • Buena Park, California • Chula Vista, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2011 · Synced Nov 3, 2026, 5:04 AM EST
Completed Phase 2 Interventional

Materna Prep Study Phase II

NCT06126328
View directory record Official record
Conditions
Vaginal Delivery, Pelvic Organ Prolapse
Interventions
Materna Prep Device
Device
Lead sponsor
Materna Medical
Industry
Eligibility
18 Years and older · Female only
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Mountain View, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Nov 3, 2026, 5:04 AM EST
Completed Phase 2 Interventional Results available

Phase IIB TL + YCWP + DC in Melanoma

NCT02301611
View directory record Official record
Conditions
Melanoma
Interventions
TLPLDC, Placebo
Drug
Lead sponsor
Elios Therapeutics, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Nov 3, 2026, 5:04 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine

NCT05027932
View directory record Official record
Conditions
Influenza
Interventions
IN Placebo, IM Placebo, BPL-1357
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Nov 3, 2026, 5:04 AM EST
Completed Phase 3 Interventional

Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder

NCT00467402
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
agomelatine, placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
78
States / cities
Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Nov 3, 2026, 5:04 AM EST
Terminated Phase 2 Interventional Results available

Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease

NCT03201445
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Filgotinib, Placebo, Standard of Care
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
21 Years to 65 Years · Male only
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
10
States / cities
San Diego, California • Lakewood Rch, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Nov 3, 2026, 5:04 AM EST
Terminated Phase 2 Interventional Results available

A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers

NCT03115801
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma
Interventions
Nivolumab, Atezolizumab, Radiation & immunotherapy, Pembrolizumab
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
19 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Nov 3, 2026, 5:04 AM EST
Not listed Not applicable Interventional

Open Label Placebo to Reduce Prescription Opioid Use

NCT05014230
View directory record Official record
Conditions
Acute Pain
Interventions
Open Placebo, Opioid medication as part of standard care
Dietary Supplement · Other
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Nov 3, 2026, 5:04 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Laser-Assisted Regenerative Surgical Therapy for Peri-implantitis

NCT03127228
View directory record Official record
Conditions
Peri-Implantitis
Interventions
Standard mechanical debridement, Er:YAG laser-assisted debridement
Other · Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Nov 3, 2026, 5:04 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of a Single Oral Dose of Moxidectin on the Cardiac QT Interval of Healthy Volunteers

NCT03012828
View directory record Official record
Conditions
QT Effects in Healthy Volunteers
Interventions
Moxidectin, Placebo
Drug · Other
Lead sponsor
Medicines Development for Global Health
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Nov 3, 2026, 5:04 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)

NCT00000767
View directory record Official record
Conditions
HIV Infections
Interventions
TBC-3B Vaccine, Smallpox Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1996
U.S. locations
5
States / cities
St Louis, Missouri • Rochester, New York • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Nov 3, 2026, 5:04 AM EST
Completed Phase 1Phase 2 Interventional

A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the Knee

NCT00944892
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
REGN475, Placebo
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
40 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Anaheim, California • Tampa, Florida • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 8, 2011 · Synced Nov 3, 2026, 5:04 AM EST
Completed Phase 1 Interventional

Randomized Controlled Trial in Liver Transplant Recipients Treated in Steroid Sparing Regimen

NCT00286871
View directory record Official record
Conditions
Chronic Hepatitis C, Organ Transplantation, Immunosuppression
Interventions
Neoral, Tacrolimus
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Nov 3, 2026, 5:04 AM EST
Completed Phase 3 Interventional

EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway

NCT05093634
View directory record Official record
Conditions
Obesity, Genetic Obesity
Interventions
Setmelanotide, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 65 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
32
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Nov 3, 2026, 5:04 AM EST
Completed Phase 3 Interventional Results available

A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)

NCT03176134
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
Tedizolid phosphate, Comparator
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Day to 11 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
San Diego, California • Chicago, Illinois • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Nov 3, 2026, 5:04 AM EST
Completed Not applicable Interventional Results available

A Randomized Controlled Trial of AppS to Home Monitor Your Asthma

NCT04401332
View directory record Official record
Conditions
Asthma
Interventions
Mobile health app
Other
Lead sponsor
RAND
Other
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Nov 3, 2026, 5:04 AM EST